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• Approximately 20% to 25% of patients with CRC have metastatic disease (mCRC) at diagnosis, and up to 50% of all patients will develop metastases, which are associated with signifi cant morbidity and diminished quality of life.
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• Panitumumab (a monoclonal antibody against epidermal growth factor receptor [EGFR]), as well as bevacizumab (a vascular endothelial growth factor [VEGF] inhibitor) in combination with chemotherapy are both options in the treatment of patients with wild-type RAS mCRC. 3, 4 • In 2007, panitumumab was initially approved by the European Medicines Agency (EMA) for patients with refractory mCRC with nonmutated (wild-type) KRAS genes.
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• Identifi cation of additional RAS mutations beyond KRAS exon 2 (i.e., mutations in KRAS exons 3 and 4 and NRAS exons 2, 3, and 4) predict lack of response to panitumumab and have driven new labels for EGFR inhibitors.
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• The European Committee for Medicinal Products for Human Use (CHMP) stated recently that the benefi t-risk balance of panitumumab has improved in its newly approved wild-type RAS indications, due to the exclusion of patients with additional RAS mutations outside those initially investigated in the KRAS exon 2 analyses.
• In such a context of improved benefi t-risk balance of panitumumab, a legitimate question arises regarding the relative value for money of panitumumab versus bevacizumab given the health care costs challenges faced in France and in Europe generally.
• Head-to-head data are available from a prospectiveretrospective analysis of the phase 2 PEAK (NCT00819780) trial, the only fi rst-line clinical trial of panitumumab plus mFOLFOX6 (oxaliplatin, 5-fl uorouracil, and leucovorin) versus bevacizumab plus mFOLFOX6 conducted in patients with mCRC (extended RAS analysis of panitumumab plus mFOLFOX6 [n = 88] and bevacizumab plus mFOLFOX6 [n = 82]; incremental benefi t in favor of panitumumab: progression-free survival [PFS] = 2.9 months, P = 0.03; overall survival [OS] = 12.4 months, P = 0.06; event rate = 41.1%, hazard ratio = 0.63; 95% CI 0.39-1.02, P = 0.06).
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OBJECTIVE
• To evaluate the cost-effectiveness of fi rst-line treatment with panitumumab plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in patients with mCRC in the wild-type RAS setting using data from the head-to-head PEAK trial.
6
METHODS
• A semi-Markov model structure was selected to assess the cost-effectiveness of panitumumab plus mFOLFOX6 relative to bevacizumab plus mFOLFOX6 in the fi rst-line treatment of patients with mCRC ( Figure 1 ).
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• The model used a 2-week cycle length and lifetime time horizon of a patient with mCRC. The analysis began with a cohort of patients initiating fi rst-line mCRC treatment and concluded when the entire patient cohort had died.
• The analysis was performed from a French health collective perspective using data from a prospective-retrospective analysis of the phase 2 PEAK clinical trial of panitumumab versus bevacizumab in fi rst-line mCRC treatment. • The model population was based on a subset of the patient population from the PEAK trial and was defi ned as previously untreated adults (aged ≥18 years) who had been diagnosed with wild-type RAS (i.e., no mutation in exons 2, 3, or 4 of KRAS and NRAS) mCRC.
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• Transition probabilities to disease progression and death for panitumumab plus mFOLFOX6 and bevacizumab plus mFOLFOX6 were based on parametric survival curves estimated in a patient-level analysis of PFS and OS from the PEAK clinical trial (coded in SAS [version 9.3; Cary, North Carolina] using the LIFEREG procedure). The PFS and OS Kaplan-Meier (K-M) plots and the fi tted PFS and OS curves for panitumumab plus mFOLFOX6 and bevacizumab plus mFOLFOX6 were estimated using exponential, Weibull, and log-logistic statistical distributions for each treatment ( Figure 2 ).
• The Weibull distribution was selected as the best-fi tted curve for both PFS and OS based on graphical overlay of the curves and the K-M plot, goodness-of-fi t statistics (Akaike information criterion), and face validity of long-term survival projections.
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• Resection-related transition probabilities based on PEAK clinical trial data were used to model the number of resection attempts, the probability that an attempt results in complete removal or reduction of the tumor, and the mean time to resection for patients with wild-type RAS mCRC.
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• Disease-free survival and OS for patients with a successful resection were modelled using parametric survival modelling and data from a study describing a population of unresectable patients that became resectable after chemotherapy.
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• Drug-acquisition costs were calculated from 2013 French Health National Insurance costs.
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Consumption of drugs, defi ned as the average number of vials consumed per administration per patient, and the average number of cycles administered were calculated from data in the PEAK clinical trial for direct treatment comparators (Table 1 ).
• Nondrug medical costs considered by the model include RAS mutation testing, drug administration, chemotherapy, physician visits, diagnostic tests, resection, subsequent treatment, and BSC (Table 2 ).
• Costs of serious adverse events were modeled based on the incidence seen in the PEAK trial 6 and costs extracted from the literature.
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• Duration of subsequent therapy was modeled via median PFS for second-line treatments from the published literature by assuming an exponential distribution. 15, 16 • Utility weights used in the model were calculated from the EuroQol-5 Dimensions (EQ-5D) questionnaire responses 17 from patients with wild-type RAS mCRC in the fi rst-line PRIME (NCT00364013) clinical trial (0.821), 5 patients with wild-type KRAS mCRC in the second-line panitumumab (NCT00339183) clinical trial (0.782), 15 and patients receiving BSC in the thirdline panitumumab (NCT00113763) clinical trial (0.681).
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• The model outcomes calculated for each fi rst-line treatment regimen included patient survival (life-years), quality-adjusted life-years (QALYs), costs for health care resources, and incremental cost-effectiveness ratios.
• To test the robustness of the model, one-way sensitivity analyses and a probabilistic sensitivity analysis were conducted.
• All costs were reported in 2013 Euros, and all costs and outcomes (benefi ts) in the model were discounted using the suggested discount rate in France of 4.0% per annum.
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RESULTS
• In the base-case analysis of the cost-effectiveness model, head-to-head clinical trial data incorporated from the PEAK study led to greater projected life-years and QALYs for patients with wild-type RAS mCRC who received panitumumab plus mFOLFOX6 versus bevacizumab plus mFOLFOX6.
• Key cost drivers included monoclonal antibody drugacquisition costs (40% to 44% of total costs) followed by BSC costs (23% to 25% of total costs); costs for serious adverse event treatment accounted for a minor percentage of the total cost in both treatments.
• Most costs were logically higher for panitumumab plus mFOLFOX6 due to greater PFS (longer duration of therapy) and greater OS (longer duration of BSC) ( Table 3 ).
• The incremental cost per life-year gained was estimated to be €26,918, and the incremental cost per QALY gained was estimated to be €36,577.
• The one-way sensitivity analysis indicated that drugacquisition costs, costs of BSC, and costs of subsequent treatments were the most sensitive model parameters.
• Results of the cost-effectiveness scatter plot showed panitumumab plus mFOLFOX6 generally to be more effective than bevacizumab plus mFOLFOX6 in a majority of the runs of the probabilistic sensitivity analysis, with more than 96% of simulations performed falling in the fi rst/northeast (more effective, more costly) cost-effectiveness quadrant ( Figure 3 ).
• Given no specifi ed willingness-to-pay threshold in France, we examined cost-effectiveness across a range of possible thresholds. Mean net monetary benefi ts from 10,000 simulations of the probabilistic sensitivity analysis indicated that 54.0% of simulations were below a willingness-to-pay threshold of €40,000, and 82.5% of simulations were below a willingness-to-pay threshold of €60,000 ( Figure 3 ).
CONCLUSION
• Model results indicated that panitumumab plus mFOLFOX6 represented good value for money compared with a current standard of care, bevacizumab plus mFOLFOX6 and, with a willingness-to-pay ranging from €40,000 to €60,000, can be considered cost-effective in the fi rst-line treatment of patients with wild-type RAS mCRC. -€34,500 -€14,500 €5,500 €25,500 €45,500 €65,500 €85,500 0%   10%   20%   30%   40%   50%   60%   70%   80%   90%   100%   €0 €10,000 €20,000 €30,000 €40,000 €50,000 €60,000 €70,000 €80,000
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• Table 4 lists the standard distribution for each set of model inputs varied in the probabilistic sensitivity analysis.
